Simulations Plus Q1 2025 Earnings Report
Key Takeaways
Simulations Plus reported a 31% increase in total revenue for the first quarter of fiscal year 2025, primarily driven by a 41% increase in software revenue. The company's MonolixSuiteâ„¢ and Quantitative Systems Pharmacology (QSP) business units showed significant growth. However, the services segment faced temporary headwinds due to client-driven data delays.
Total revenue increased 31% to $18.9 million.
Software revenue increased 41% to $10.7 million, representing 57% of total revenue.
Services revenue increased 19% to $8.2 million, representing 43% of total revenue.
Adjusted EBITDA of $4.5 million, representing 24% of total revenue, compared to $3.4 million, representing 23% of total revenue.
Simulations Plus
Simulations Plus
Simulations Plus Revenue by Segment
Simulations Plus Revenue by Geographic Location
Forward Guidance
Simulations Plus provided its fiscal year 2025 guidance, expecting revenue between $90 million and $93 million, representing a growth of 28-33%. They anticipate the software mix to be between 55-60% and adjusted EBITDA margin between 31-33%. Adjusted diluted EPS is expected to be between $1.07 and $1.20.
Positive Outlook
- Revenue between $90M - $93M
- Revenue growth 28 - 33%
- Software mix 55 - 60%
- Adjusted EBITDA margin 31 - 33%
- Adjusted diluted EPS $1.07 - $1.20
Revenue & Expenses
Visualization of income flow from segment revenue to net income